KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) EBIT (2016 - 2025)

Historic EBIT for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $8.9 billion.

  • Eli Lilly's EBIT rose 6680.34% to $8.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $29.2 billion, marking a year-over-year increase of 8055.57%. This contributed to the annual value of $29.2 billion for FY2025, which is 8055.5% up from last year.
  • As of Q4 2025, Eli Lilly's EBIT stood at $8.9 billion, which was up 6680.34% from $8.0 billion recorded in Q3 2025.
  • Over the past 5 years, Eli Lilly's EBIT peaked at $8.9 billion during Q4 2025, and registered a low of $1.4 billion during Q2 2021.
  • In the last 5 years, Eli Lilly's EBIT had a median value of $2.6 billion in 2022 and averaged $3.6 billion.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 3777.97% in 2023, then soared by 10106.13% in 2025.
  • Eli Lilly's EBIT (Quarter) stood at $2.4 billion in 2021, then fell by 11.82% to $2.1 billion in 2022, then skyrocketed by 44.94% to $3.0 billion in 2023, then surged by 77.35% to $5.3 billion in 2024, then skyrocketed by 66.8% to $8.9 billion in 2025.
  • Its EBIT was $8.9 billion in Q4 2025, compared to $8.0 billion in Q3 2025 and $7.0 billion in Q2 2025.